GlassScriptPhysician profile
Scott J Swanson
NPI 1396782421
$49,225.00
in general payments reported to CMS, 2019-2025
11 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,673 · 2020: $12K · 2021: $12K · 2022: $10K · 2023: $1,498 · 2024: $3,680 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,060 · Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,060.00 |
| Food and Beverage | $245.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $23,283.44 | 2019-2024 | Echelon Flex, Harmonic, Surgicel Nu-Knit |
| Ethicon INC. | $11,960.00 | 2020-2021 | |
| Ethicon US, LLC | $8,902.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $3,987.50 | 2022 | |
| Medtronic USA, INC. | $646.18 | 2020 | |
| Intuitive Surgical, INC. | $173.47 | 2020 | |
| Medtronic, INC. | $127.52 | 2025 | Eea |
| Astrazeneca Pharmaceuticals LP | $117.59 | 2023 | Tagrisso |
| Aesculap Ag | $26.39 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.